For Novartis Pharmaceuticals, Settling Allegations of Improper Payments Came at an Over $642 Million-dollar Price.
The dual settlements represent the Department of Justice’s continued crackdown on possible False Claims Act violations. Novartis Pharmaceuticals Corporation reached an over $642 million-dollar agreement